Document is current
Any future updates will be listed below
-
Authors
Waltman, Peter
Chandra, Pooja
Eng, Ken W.
Wilkes, David C.
Park, Hyeon
Pabon, Carlos
Delpe, Princesca
Bhinder, Bhavneet
Manohar, Jyothi
Kane, Troy
Fernandez, Evan
Gorski, Kathryn
Greco, Noah
Simi, Manuele
Tang, Jeffrey M.
Zisimopoulos, Pantelis
King, Abigail
Al Assaad, Majd
Ten Eyck, Theresa
Roberts, Douglas
Monge, Jorge
Demichelis, Francesca
Tam, Wayne
Ouseph, Madhu M.
Sigaras, Alexandros
Beltran, Himisha
Rennert, Hannah
Lindeman, Neal
Song, Wei
Solomon, James
Mosquera, Juan Miguel
Kim, Rob
Catalano, Jeffrey
Hassane, Duane C.
Sigouros, Michael
Elemento, Olivier
Alonso, Alicia
Sboner, Andrea
-
Funding
Funding for this research was provided by:
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
WCM Myeloma Center, Weill Cornell Medicine, New York, NY
Department of Medicine, Weill Cornell Medicine, New York, NY
Meyer Cancer Center, Weill Cornell Medicine, New York, NY
- License Information
-
More Information
Article History
Received: 7 May 2025
Accepted: 16 March 2026
First Online: 21 April 2026
Competing interests
: Theresa Ten Eyck, Douglas Roberts, and Carlos Pabon are or were employees of Agilent Technologies, the maker/producer of the EXaCT-2 assay. The other authors do not have a competing interest.
